Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Type 1 Diabetes, Diabetes Mellitus, Peripheral Diabetic Neuropathy

In brief

The purpose of this study is to assess safety and tolerability and determine the pharmacokinetics of subcutaneous single and multiple (up to 12) dose administration of CBX129801 (long-acting synthetic C-peptide) in type 1 diabetes patients.

Key facts

Study ID

NCT01293461

Run by

Cebix Incorporated

People needed

72

Starts

2011-04-01

Expected to finish

2012-10-01

Last updated by the study team

2013-03-01

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Escondido, California, United States
• Study site — Tustin, California, United States
• Study site — Walnut Creek, California, United States
• Study site — Aurora, Colorado, United States
• Study site — Butte, Montana, United States
• Study site — San Antonio, Texas, United States
• Study site — Olympia, Washington, United States
• Study site — Renton, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.